| Code | CSB-RA023986MB8HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to Narlumosbart, targeting TNFSF11 (Tumor Necrosis Factor Superfamily Member 11), also known as RANKL (Receptor Activator of Nuclear Factor Kappa-B Ligand). TNFSF11 is a critical cytokine that regulates bone metabolism by promoting osteoclast differentiation, activation, and survival. This protein plays a central role in bone remodeling and calcium homeostasis, and its dysregulation is implicated in various skeletal disorders including osteoporosis, bone metastases, and rheumatoid arthritis. Additionally, TNFSF11 functions in immune system regulation, lymph node development, and mammary gland morphogenesis.
Narlumosbart is a therapeutic monoclonal antibody designed to neutralize TNFSF11, thereby inhibiting osteoclast-mediated bone resorption. This biosimilar antibody serves as a valuable research tool for investigating RANKL-RANK signaling pathways, studying bone metabolism mechanisms, exploring skeletal disease pathogenesis, and evaluating potential therapeutic interventions for conditions characterized by excessive bone loss or abnormal bone remodeling. It enables researchers to examine the molecular mechanisms underlying osteoclastogenesis and bone-immune system interactions.
There are currently no reviews for this product.